Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC

Reuters12-11

Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC

Hansoh Pharmaceutical Group Co. Ltd. has announced updated results from a Phase I/II clinical trial evaluating resencatinib (HS-10365), a highly selective RET inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring RET gene fusions. The data, presented at the ESMO ASIA Congress 2025, included findings from 326 patients with RET-altered advanced solid tumors. In the study, the confirmed objective response rate $(ORR)$ was 80.0% in patients who had progressed after previous therapies, and 83.3% in treatment-naive patients. The disease control rate (DCR) was 96.0% and 93.3%, respectively, with 12-month progression-free survival rates of 81.1% and 79.3%. Resencatinib demonstrated a favorable tolerability and manageable safety profile in this population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590161594?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 18:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590161594","market":"fut","top_or_hot":-1,"title":"Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co. Ltd. has announced updated results from a Phase I/II clinical trial evaluating resencatinib (HS-10365), a highly selective RET inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring RET gene fusions. The data, presented at the ESMO ASIA Congress 2025, included findings from 326 patients with RET-altered advanced solid tumors. In the study, the confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> was 80.0% in patients who had progressed after previous therapies, and 83.3% in treatment-naive patients. The disease control rate (DCR) was 96.0% and 93.3%, respectively, with 12-month progression-free survival rates of 81.1% and 79.3%. Resencatinib demonstrated a favorable tolerability and manageable safety profile in this population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 18:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co. Ltd. has announced updated results from a Phase I/II clinical trial evaluating resencatinib (HS-10365), a highly selective RET inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring RET gene fusions. The data, presented at the ESMO ASIA Congress 2025, included findings from 326 patients with RET-altered advanced solid tumors. In the study, the confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> was 80.0% in patients who had progressed after previous therapies, and 83.3% in treatment-naive patients. The disease control rate (DCR) was 96.0% and 93.3%, respectively, with 12-month progression-free survival rates of 81.1% and 79.3%. Resencatinib demonstrated a favorable tolerability and manageable safety profile in this population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7sL9Hy:1","article_id":"2590161594","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590161594","pubTimestamp":1765447750,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co. Ltd. has announced updated results from a Phase I/II clinical trial evaluating resencatinib , a highly selective RET inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer  harboring RET gene fusions. The data, presented at the ESMO ASIA Congress 2025, included findings from 326 patients with RET-altered advanced solid tumors. In the study, the confirmed objective response rate  was 80.0% in patients who had progressed after previous therapies, and 83.3% in treatment-naive patients. The disease control rate  was 96.0% and 93.3%, respectively, with 12-month progression-free survival rates of 81.1% and 79.3%. Resencatinib demonstrated a favorable tolerability and manageable safety profile in this population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1589":"北水核心资产","03692":"翰森制药","BK1583":"高瓴概念"},"translate_title":"翰森制药报告Resencatinib治疗RET-Fusion非小细胞肺癌的强劲II期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC\n    \n\n        Hansoh Pharmaceutical Group Co. Ltd. has announced updated results from a Phase I/II clinical trial evaluating resencatinib (HS-10365), a highly selective RET inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring RET gene fusions. The data, presented at the ESMO ASIA Congress 2025, included findings from 326 patients with RET-altered advanced solid tumors. In the study, the confirmed objective response rate $(ORR)$ was 80.0% in patients who had progressed after previous therapies, and 83.3% in treatment-naive patients. The disease control rate (DCR) was 96.0% and 93.3%, respectively, with 12-month progression-free survival rates of 81.1% and 79.3%. Resencatinib demonstrated a favorable tolerability and manageable safety profile in this population.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590161594","isCrawlerRequest":true}